Shots:
FDA has accepted BLA for I-DXd under the RTOR & Project Orbis program, granting priority review for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease progressed on or after Pt-based CT (PDUFA: Oct 10, 2026)
BLA was based on the P-II (IDeate-Lung01) study assessing I-DXd (IV, Q3W) in…
